media – Page 3 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Another powerful tool has been added to Qilu Pharmaceutical’s arsenal, with another blockbuster drug receiving market approval

Parkinson’s disease is a common neurodegenerative disease that causes great inconvenience to patients’ lives. Especially in the middle and late stages, patients often face severe deterioration of motor function, such as recurrent episodes of muscle stiffness, tremors, and difficulty moving, which greatly reduces their quality of life. On June 9, 2026 , according to the latest information on the official website of the National Medical Products Administration ( NMPA ) of China, salfedipine mesylate tablets , submitted by Qilu Pharmaceutical Co., Ltd. under Category 4 of chemical drug registration , were approved for marketing and are considered to have passed the evaluation. It is mainly used to treat idiopathic Parkinson’s disease in patients who experience motor fluctuations after receiving stable doses of levodopa. Safinamide mesylate tablets are a selective inhibitor of monoamine oxidase type B (MAO-B) with a unique mechanism of action that reduces dopamine degradation and regulates glutamate release, ...
- Source: drugdu
- 86
- June 10, 2026
Huadong Medicine’s application for a change of indication for its Yiyanshi® S-type forehead filler has been accepted, potentially marking another step forward in its high-end regenerative filler business.

On June 9, Huadong Medicine (000963.SZ) announced that its application for a new indication for Ellansé® S – type , an imported Class III medical device injectable polycaprolactone microsphere facial filler , for subcutaneous or suprapeophyte implantation in the forehead to improve moderate to severe forehead contour defects, has been formally accepted by the National Medical Products Administration (NMPA). This application is expected to expand its scope from nasolabial folds to the forehead contour area, strengthening the company’s multi-indication competitive advantage in the PCL regeneration field and enriching its supply of refined facial anti-aging solutions, further releasing the product’s clinical value. Ellansé® is one of the core products of Huadong Medicine Aesthetics , and is known as the ” Youthful Needle” due to its outstanding triple effect of “immediate filling + long-lasting maintenance + natural metabolism”. As the first approved imported PCL high-end facial filler in China, the application for ...
- Source: drugdu
- 93
- June 10, 2026
Inpacpen DCP®, a pen injector made in China, has obtained FDA approval in the United States, ushering in a new era for drug-device combination products going global!

Recently , a strategic partner of Shanghai Newyao Baike Medical Technology Co., Ltd. (Shanghai Newyao Baike Medical Technology Co., Ltd.) received formal approval from the U.S. Food and Drug Administration (FDA) for its Inpacpen DCP® disposable adjustable-dose cartridge injection pen, successfully approved for use in its liraglutide injection! This is the first drug-device combination product approved by the FDA using a pen syringe manufactured in China, marking a historic step for China’s high-end drug delivery devices in entering the international market with the highest regulatory standards. It is also the company’s third product to receive approval in the U.S. market, following the Safetis® needle protector and the InpacJector® Luer pre-filled syringe (COP)!A historic breakthrough in China’s drug-medicine combination products Liraglutide, a blockbuster GLP-1 drug, has long relied on European and American suppliers for its delivery devices. This approval signifies that Chinese-made pen injectors have officially entered the world’s most stringent ...
- Source: drugdu
- 76
- June 10, 2026
【EXPERT Q&A】How long does it take to obtain a medical device registration certificate for exporting Chinese medical devices to Malaysia?

Drugdu.com expert’s response: The time required to obtain an MDA medical device registration certificate for exporting Chinese medical devices to Malaysia mainly depends on the product risk class and whether an expedited pathway is used. Standard Processing Time (No Expedited Pathway) Under Malaysia’s Medical Device Act 2012, products are classified into four risk categories: Class A (Low Risk): e.g., gauze bandages, medical rubber plaster, cooling oil → 6–9 months Class B (Moderate-Low Risk): e.g., povidone-iodine solution, disposable sterile obstetric surgical pack → 9–12 months Class C (Moderate-High Risk): 12–18 months Class D (High Risk): 18–24 months Expedited Pathway: As Fast As 30 Working Days This is currently the most notable channel. Malaysia and China have launched a regulatory cooperation program. Products holding a China NMPA registration certificate can apply through the MDA Verification Pathway via a CAB (Conformity Assessment Body) assessment, shortening the approval time to approximately 30 working days. Eligibility: hold NMPA / CE / FDA / TGA registration from ...
- Source: drugdu
- 81
- June 10, 2026
QMEE QINGDAO

Organiser：Asia Economic & Trade Development Promotion Center, China Council for the Promotion of International Trade Shandong Provincial Committee, Qingdao Medical Association Time：July 2–4, 2026 Address：Qingdao International Convention and Exhibition Center, No. 9 Miaoling Road, Laoshan District, Qingdao Exhibition hall：Qingdao International Convention and Exhibition Center Product range: Diagnostic & Treatment Equipment: X-ray imaging, ultrasound diagnostics, endoscopy systems, monitoring equipment, scanning devices, optical instruments, and examination/diagnostic equipment for neurology, orthopedics, ENT, ophthalmology, pathology, etc. Laboratory: Testing instruments, laboratory equipment, biochemical analysis & diagnostic reagents, sterilization & disinfection equipment, cleanroom engineering, gas supply systems, cryogenic & freezing equipment, etc. Rehabilitation & Nursing: Various therapeutic devices, rehabilitation training equipment, nursing instruments, special mobility aids, barrier-free facility series, healthcare equipment, assistive devices. Digital Healthcare: Intelligent examination & checkup devices, Medical Image Archiving & Communication System (PACS), Hospital Information System (HIS), digital community healthcare systems, telemedicine systems, healthcare information solutions, medical software development, electronic medical ...
- Source: drugdu
- 98
- June 9, 2026
Jingfang Pharmaceuticals’ small molecule drug receives Fast Track designation from the US FDA for lung cancer

On June 5th, GenFang Pharmaceuticals announced that GFH375/VS-7375 ( an oral KRAS G12D inhibitor ) received Fast Track Designation (FTD) from the U.S. FDA for the treatment of previously treated patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) with KRAS G12D mutations (concurrent or sequentially treated with platinum-based chemotherapy and PD-1/PD-L1 inhibitors) . Previously, GFH375/VS-7375 received another Fast Track Designation from the FDA last year for the treatment of first-line and later-line KRAS G12D -mutant metastatic pancreatic ductal adenocarcinoma (PDAC). Furthermore, GFH375 has already received two Breakthrough Therapy Designations (BTD) in China this year for monotherapy in KRAS G12D -mutant advanced pancreatic cancer and NSCLC. GFH375 is an orally administered, highly active, and selective small-molecule KRAS G12D (ON/OFF) inhibitor. It binds to the KRAS G12D protein non-covalently, inhibiting its binding to downstream effector proteins, thereby disrupting the sustained activation of downstream pathways by KRAS G12D in ...
- Source: drugdu
- 84
- June 8, 2026
Once a month! The world’s first new drug for IgA nephropathy has been approved for marketing in China.

Yesterday (June 4), the official website of the National Medical Products Administration (NMPA) showed that Otsuka Pharmaceutical’s application for Sibeprenlimab injection was conditionally approved for marketing, for the treatment of adult patients with primary immunoglobulin A nephropathy (IgAN) to maintain their kidney function. This application had previously been included in the priority review list. Sbelimab is the world’s first approved monoclonal antibody drug targeting the inhibition of proliferation-inducing ligand (APRIL) . Its approval in China marks a new stage in the treatment of IgA nephropathy in China, moving from traditional supportive care to precise intervention targeting upstream causes. 01 IgA nephropathy is highly prevalent and difficult to treat. IgA nephropathy is the most common primary glomerular disease in China, with a patient population of over 2.2 million. The disease is concentrated in young adults aged 16 to 40 and is the leading cause of progression to end-stage renal disease (uremia) ...
- Source: drugdu
- 83
- June 8, 2026
The world’s first Class 1 new drug from a Guangdong pharmaceutical company has been approved for marketing

Mantle cell lymphoma (MCL) combines the highly progressive nature of aggressive lymphoma with the incurable nature of indolent lymphoma. Most patients are diagnosed at an advanced stage, often with involvement of lymph nodes, bone marrow, gastrointestinal tract, and extranodal organs. The successive availability of previous generations of BTK inhibitors has significantly improved patient prognosis, but drug resistance and relapse remain a major challenge to long-term survival. On June 4, 2026, according to the latest information on the official website of the National Medical Products Administration (NMPA) of China, the Class 1 innovative drug lobrutinib tablets submitted by Guangzhou Lupeng Pharmaceutical Co., Ltd. was approved for marketing . The drug is indicated for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least two systemic therapies (including Bruton’s tyrosine kinase [BTK] inhibitors) . According to publicly available information, lobubrutinib is the world’s first fourth-generation covalent ...
- Source: drugdu
- 73
- June 8, 2026
GenSci Pharmaceutical’s self-developed Class 1 new drug has been approved for clinical trials for two indications, covering pediatrics and neurology.

Recently, GenSci155 injection, independently developed by Changchun GenSci Pharmaceutical Co., Ltd. (hereinafter referred to as “GenSci Pharmaceutical”), has been approved by the National Medical Products Administration to conduct clinical trials. It is intended for the prevention of bronchopulmonary dysplasia (BPD) in premature infants and the treatment of acute ischemic stroke (AIS). GenSci Pharmaceutical will subsequently conduct further clinical research in the fields of pediatric health and neuroprotection. GenSci155 injection is a long-acting fatty acid-conjugated recombinant human insulin-like growth factor-1 (IGF-1) analogue, registered as a Class 1 therapeutic biological product. Developed based on GenSci Pharmaceutical’s Duratide™ long-acting sustained-release peptide platform, this product achieves reversible binding to albumin through fatty acid chain modification, prolonging the drug’s half-life in vivo. It supports both intravenous and subcutaneous administration, extending dosing intervals and contributing to stable and adequate drug exposure. Indication 1 Prevention of bronchopulmonary dysplasia (BPD) in premature infants Bronchopulmonary dysplasia (BPD) is the most common pulmonary ...
- Source: drugdu
- 65
- June 8, 2026
Yunnan Baiyao Group’s Central Research Institute’s INB301 injection IND has received FDA clinical trial approval, achieving a milestone breakthrough with “dual applications in China and the United States”

On June 2, 2026, the innovative biological drug INB301 injection, developed by the Central Research Institute of Yunnan Baiyao Group (hereinafter referred to as the “Central Research Institute”), officially obtained Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). Previously, the product had received clinical trial approval from the China National Medical Products Administration (NMPA) on March 30, 2026. The consecutive successful clinical reviews by the drug regulatory agencies of both China and the United States for INB301 injection marks a key advancement for Yunnan Baiyao in its global innovative drug strategy, achieving a significant breakthrough in “dual application” between China and the U.S.Aligning with international standards and setting a new benchmark for Sino-US dual reporting”Dual application in China and the US” is an important indicator of an innovative pharmaceutical company’s R&D strength and its ability to align with international standards. The fact that INB301 injection ...
- Source: drugdu
- 71
- June 8, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.